CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6900 result(s)

Consultation on Drug Reviews: Webinar for Patient Groups

Event Date: July 9, 2020
Result type: Events

Patient groups and other stakeholders are invited to comment on a revised procedure for CADTH’s drug reimbursement review processes (that is, the pan-Canadian Oncology Drug Review, the Common Drug Review, and the Interim Plasma Protein Product Review).  To help patient groups and patients contribute to the consultation, this webinar will h...

New at CADTH - July 2020

Last Updated: July 8, 2020
Result type: Reports
Product Line: New at CADTH

News and Events CADTH is proud to announce that Suzanne McGurn has officially started her role as the new President and Chief Executive Officer of CADTH. Ms. McGurn was appointed by the CADTH Board of Directors after a comprehensive search that was international in scope. She brings to CADTH significant leadership experience and a deep und...

Cone Beam CT in Dental and Other Settings

Last Updated: July 8, 2020
Result type: Reports
Product Line: Environmental Scans

The main objective of this Environmental Scan is to inform Health Canada’s regulation of cone beam CT (CBCT) device manufacturers. It is not intended as an assessment of individual clinical practice. The key objectives of this Environmental Scan are to: determine procedures for which CBCT is commonly used identify the professionals conducti...

  • Project Number: ES0348-000

Firazyr (icatibant) (Firazyr)

Last Updated: July 8, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: icatibant
Indications: Acute attacks of hereditary angioedema in adolescents and children aged two years and older with C1-esterase inhibitor deficiency

  • Brand Name: Firazyr
  • Manufacturer: Takeda Canada Inc.
  • Project Status: Not filed
  • Submission Type: Non-submission

Halobetasol propionate and tazarotene (Duobrii)

Last Updated: July 7, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: Halobetasol propionate and tazarotene
Indications: Psoriasis, moderate to severe plaque

  • Brand Name: Duobrii
  • Manufacturer: Bausch Health, Canada Inc.
  • Project Number: SR0638-000
  • Project Status: Active
  • Submission Type: New

filgotinib (TBC)

Last Updated: July 6, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: filgotinib
Indications: Arthritis, Rheumatoid

  • Brand Name: TBC
  • Manufacturer: Gilead Sciences Canada, Inc.
  • Project Number: SR0656-000
  • Project Status: Pending
  • Submission Type: New

glycopyrrolate (Cuvposa)

Last Updated: July 6, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: glycopyrrolate
Indications: chronic severe drooling, neurologic (pediatric)

  • Brand Name: Cuvposa
  • Manufacturer: MEDEXUS Pharmaceuticals, Inc.
  • Project Number: SR0613-000
  • Project Status: Active
  • Submission Type: New

eculizumab (Soliris)

Last Updated: July 3, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: eculizumab
Indications: Neuromyelitis optica spectrum disorder

  • Brand Name: Soliris
  • Manufacturer: Alexion Pharma Canada Corp.
  • Project Number: SR0640-000
  • Project Status: Active
  • Submission Type: New